These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10719809)

  • 41. Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype.
    Nakano I; Fukuda Y; Katano Y; Toyoda H; Hayashi K; Hayakawa T; Kumada T; Nakano S
    Gut; 2001 Aug; 49(2):263-7. PubMed ID: 11454804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment.
    Miyajima I; Sata M; Kumashiro R; Uchimura Y; Ide T; Suzuki H; Tanikawa K
    Oncol Rep; 1998; 5(1):201-4. PubMed ID: 9458322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of transforming growth factor beta-1 in chronic hepatitis and hepatocellular carcinoma associated with hepatitis C virus infection.
    Kim HG; Chung YH; Song BC; Kim J; Yang SH; Lee YS; Suh DJ
    Korean J Intern Med; 2000 Dec; 15(3):165-70. PubMed ID: 11242803
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong population.
    Zhou XM; Chan PK; Tam JS
    World J Gastroenterol; 2011 Dec; 17(48):5317-23. PubMed ID: 22219602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies.
    De Mitri MS; Mele L; Morsica G; Chen CH; Sitia G; Gramenzi A; Andreone P; Alberti A; Bernardi M; Pisi E
    J Med Virol; 2000 Feb; 60(2):133-8. PubMed ID: 10596011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of HCV-specific sequences in chronic myopathy with hepatitis C: improvement with interferon-alpha 2A therapy.
    Sola P; Galassi G; Merelli E; Ferrari MG; Sorgato P; Ghini M
    Eur Neurol; 1999; 42(3):181-3. PubMed ID: 10529547
    [No Abstract]   [Full Text] [Related]  

  • 47. [Implication of mutation of hepatitis C virus 1b interferon sensitivity determining region(NS5A aa 2209-2248) response to interferon alpha therapy in patients with chronic hepatitis C].
    Tang Z; Köck J; Moradpour D; Yang D; Hao L; Blum H
    J Tongji Med Univ; 1999; 19(2):115-9. PubMed ID: 12840853
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression.
    Miura M; Maekawa S; Takano S; Komatsu N; Tatsumi A; Asakawa Y; Shindo K; Amemiya F; Nakayama Y; Inoue T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
    J Virol; 2013 Dec; 87(23):12541-51. PubMed ID: 23946458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secondary structure of the hepatitis C virus 5' untranslated region and efficacy of interferon therapy for chronic hepatitis C.
    Suzuki K; Shinzawa H; Kuboki M; Ishibashi M; Yoshii E; Saito T; Takahashi T
    Liver; 1998 Oct; 18(5):331-6. PubMed ID: 9831362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic changes in the interferon sensitivity determining region of hepatitis C virus during the natural course of chronic hepatitis C.
    Maekawa S; Enomoto N; Kurosaki M; Nagayama K; Marumo F; Sato C
    J Med Virol; 2000 Jul; 61(3):303-10. PubMed ID: 10861637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection.
    Watanabe H; Enomoto N; Nagayama K; Izumi N; Marumo F; Sato C; Watanabe M
    J Infect Dis; 2001 Apr; 183(8):1195-203. PubMed ID: 11262201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients.
    Ikeda K; Kobayashi M; Saitoh S; Someya T; Hosaka T; Akuta N; Suzuki F; Tsubota A; Suzuki Y; Arase Y; Kumada H
    Oncology; 2003; 65(3):204-10. PubMed ID: 14657593
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Analysis of genome character and amino acid residues 2,209 to 2,248 of NS5 A region of hepatitis C virus in relation to the response to interferon therapy].
    Duan X; Zhu C; Cheng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):368-70. PubMed ID: 12759980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Hisanaga Y
    Cancer; 2000 Jan; 88(1):58-65. PubMed ID: 10618606
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Screening for genetic heterogeneity in the interferon sensitivity determining region of the hepatitis C virus genome by polymerase chain reaction with melting curve analysis.
    Sasaki D; Sugahara K; Inokuchi N; Yanagihara K; Hasegawa H; Mori S; Yamada Y; Kamihira S
    Clin Chem Lab Med; 2008; 46(7):966-73. PubMed ID: 18624619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection.
    Squadrito G; Orlando ME; Cacciola I; Rumi MG; Artini M; Picciotto A; Loiacono O; Siciliano R; Levrero M; Raimondo G
    J Hepatol; 1999 Jun; 30(6):1023-7. PubMed ID: 10406179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study.
    Bhebhe L; Anderson M; Souda S; Choga WT; Zumbika E; Shaver ZM; Mbangiwa T; Phinius BB; Banda CC; Melamu P; Musonda RM; Essex M; Blackard JT; Moyo S; Gaseitsiwe S
    BMC Infect Dis; 2019 Oct; 19(1):875. PubMed ID: 31640596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma.
    Donlin MJ; Lomonosova E; Kiss A; Cheng X; Cao F; Curto TM; Di Bisceglie A; Tavis JE
    PLoS One; 2014; 9(7):e103748. PubMed ID: 25079603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients.
    Le Guillou-Guillemette H; Ducancelle A; Bertrais S; Lemaire C; Pivert A; Veillon P; Bouthry E; Alain S; Thibault V; Abravanel F; Rosenberg AR; Henquell C; André-Garnier E; Petsaris O; Vallet S; Bour JB; Baazia Y; Trimoulet P; André P; Gaudy-Graffin C; Bettinger D; Larrat S; Signori-Schmuck A; Saoudin H; Pozzetto B; Lagathu G; Minjolle-Cha S; Stoll-Keller F; Pawlotsky JM; Izopet J; Payan C; Lunel-Fabiani F
    J Clin Virol; 2015 Aug; 69():203-9. PubMed ID: 26209408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients.
    El-Shamy A; Pendleton M; Eng FJ; Doyle EH; Bashir A; Branch AD
    Sci Rep; 2016 Jun; 6():27025. PubMed ID: 27246310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.